Skip to main content
Fig. 1 | Cancer Nanotechnology

Fig. 1

From: Targeting and internalizing PEGylated nanodrugs to enhance the therapeutic efficacy of hematologic malignancies by anti-PEG bispecific antibody (mPEG × CD20)

Fig. 1

Strategy by which the anti-PEG bispecific antibody (mPEG × CD20) targets PLD to CD20-expressing hematologic malignancies. The anti-PEG bispecific antibody (mPEG × CD20) can bind to the terminal methoxy groups present on PEG chains surrounding PLD and confer CD20 specificity to form αCD20/PLD. The αCD20/PLD can target to CD20+ lymphoma Raji cells, enhancing internalization, and increasing anti-cancer activity in hematologic malignancies lacking an EPR effect

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us